Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204778 | 1.00 | PAK4 (0.64) | PAK4 | |
| SCHEMBL12879416 | 0.91 | PAK4 (0.65) | PAK4 | |
| SCHEMBL15252484 | 0.91 | PAK4 (0.65) | PAK4 | |
| SCHEMBL12879441 | 0.84 | PAK4 (0.65) | PAK4 | |
| SCHEMBL1204731 | 0.83 | PAK4 (0.71) | PAK4 | |
| SCHEMBL1204730 | 0.83 | PAK4 (0.71) | PAK4 | |
| SCHEMBL14521419 | 0.82 | PAK4 (0.70) | PAK4 | |
| SCHEMBL12879428 | 0.82 | PAK4 (0.70) | PAK4 | |
| SCHEMBL15252705 | 0.82 | PAK4 (0.70) | PAK4 | |
| SCHEMBL12879426 | 0.80 | PAK4 (0.65) | PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979356-B1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PROD INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.